Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia

Previously, it has been stated that the BCR-ABL fusion-protein is sufficient to induce Chronic Myeloid Leukemia (CML), but additional genomic-changes are required for disease progression. Hence, we profiled control and tyrosine kinase inhibitors (TKI) alone or in combination with other drug-treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Neetu, Tripathi, Anil Kumar, Sahu, Dinesh Kumar, Mishra, Archana, Linan, Margaret, Argente, Bianca, Varkey, Julia, Parida, Niranjan, Chowdhry, Rebecca, Shyam, Hari, Alam, Nawazish, Dixit, Shivani, Shankar, Pratap, Mishra, Abhishek, Agarwal, Avinash, Yoo, Chris, Bhatt, Madan Lal Brahma, Kant, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084383/
https://www.ncbi.nlm.nih.gov/pubmed/30100996
http://dx.doi.org/10.18632/oncotarget.25752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084383/
https://www.ncbi.nlm.nih.gov/pubmed/30100996
http://dx.doi.org/10.18632/oncotarget.25752

Ejemplares similares